Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Coeptis Therapeutics Holdings (COEPW) Accumulated Depreciation & Amortization (2021 - 2025)

Coeptis Therapeutics Holdings has reported Accumulated Depreciation & Amortization over the past 5 years, most recently at $15217.0 for Q3 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $15217.0 for Q3 2025, up 4.48% from a year ago — trailing twelve months through Sep 2025 was $15217.0 (up 4.48% YoY), and the annual figure for FY2024 was $14777.0, up 6.07%.
  • Accumulated Depreciation & Amortization for Q3 2025 was $15217.0 at Coeptis Therapeutics Holdings, up from $15070.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for COEPW hit a ceiling of $15217.0 in Q3 2025 and a floor of $11311.0 in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $14142.0 (2024), compared with a mean of $13917.3.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 12.24% in 2022 and later grew 4.48% in 2025.
  • Coeptis Therapeutics Holdings' Accumulated Depreciation & Amortization stood at $11311.0 in 2021, then rose by 12.24% to $12695.0 in 2022, then increased by 9.74% to $13931.0 in 2023, then rose by 6.07% to $14777.0 in 2024, then grew by 2.98% to $15217.0 in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $15217.0 (Q3 2025), $15070.0 (Q2 2025), and $14924.0 (Q1 2025) per Business Quant data.